Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | OXTR | P30559 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | AURKA | O14965 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.36 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | HTR5A | P47898 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11195016 | 1.00 | GAA (0.60) | GAANPSR1MAOAMAOBCA12 | |
| Hydrochloric Acid SCHEMBL11181597 | 0.98 | GAA (0.58) | GAANPSR1MAOAMAOBCA12 | |
| Piperidine SCHEMBL5732816 | 0.88 | GAA (0.49) | GAANPSR1MAOAMAOBCA12 | |
| SCHEMBL1368071 | 0.75 | GAA (1.00) | GAANPSR1MAOAMAOBCA12 | |
| SCHEMBL18421618 | 0.75 | CHRNB2 (0.36) | GAANPSR1 | |
| SCHEMBL9025634 | 0.73 | ALDH1A1 (0.59) | GAANPSR1MAOAMAOBCA12 | |
| SCHEMBL9870497 | 0.73 | OXTR (0.52) | GAANPSR1MAOAMAOBCA12 | |
| SCHEMBL2744551 | 0.73 | EGFR (0.47) | GAANPSR1MEN1MAPTKMT2A | |
| SCHEMBL6128272 | 0.73 | MEN1 (0.36) | GAANPSR1MEN1MAPTKMT2A | |
| SCHEMBL14368234 | 0.73 | PARP10 (0.41) | GAANPSR1MAOBCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2391602-B1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-12-04 | — | — | EP | claimed |
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | claimed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | claimed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | claimed |
| EP-2391602-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-12-07 | — | — | EP | claimed |
| WO-2010080481-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | claimed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | claimed |
| EP-1805170-B1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2010-04-14 | — | — | EP | claimed |
| EP-2167498-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-03-31 | — | — | EP | claimed |
| US-7645776-B2 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | claimed |
| EP-1959951-B1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-12-23 | — | — | EP | claimed |
| US-20090099175-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2009-04-16 | — | — | US | claimed |
| WO-2008157210-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-12-24 | — | — | WO | claimed |
| EP-1989195-A1 | PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-12 | — | — | EP | claimed |
| WO-2007103260-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | claimed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | claimed |
| EP-0677516-B1 | Cyclic amide derivatives | EISAI CO LTD (JP) | 1998-09-02 | — | — | EP | claimed |
| EP-0677516-A1 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1995-10-18 | — | — | EP | claimed |
| EP-0468187-A2 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1992-01-29 | — | — | EP | claimed |
| EP-4722195-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLES | National University Corporation Hokkaido University (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-4698520-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | Gandeeva Therapeutics, Inc. (US) | 2026-02-25 | — | — | EP | disclosed |
| EP-4634158-A2 | INHIBITORS OF PROCASPASE-6 ACTIVATION AND USES THEREOF | The Regents of University of California (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-4559896-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE | National University Corporation Hokkaido University (JP) | 2025-05-28 | — | — | EP | disclosed |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2024-12-12 | — | — | US | disclosed |
| WO-2024248146-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLES | 国立大学法人北海道大学 | 2024-12-05 | — | — | WO | disclosed |
| WO-2024220708-A1 | RAF-MEK PROTEIN COMPLEX MODULATORS AND METHODS OF USE THEREOF | GANDEEVA THERAPEUTICS, INC. (US) | 2024-10-24 | — | — | WO | disclosed |
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024129892-A2 | INHIBITORS OF PROCASPASE-6 ACTIVATION AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024018762-A1 | PH-SENSITIVE CATIONIC LIPID AND LIPID NANOPARTICLE | 国立大学法人北海道大学 | 2024-01-25 | — | — | WO | disclosed |
| US-20230416262-A1 | TRPML MODULATORS | CASMA THERAPEUTICS, INC. | 2023-12-28 | — | — | US | disclosed |
| WO-2023059609-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| US-11584717-B2 | MIF modulators | YALE UNIVERSITY (US) | 2023-02-21 | — | — | US | disclosed |
| CN-110372625-B | Method for preparing 4-alkyl methyl-4-aryl-1,3-benzoxazine-2 (4H) -ketone by blue light irradiation | 常州大学 | 2022-11-01 | — | — | CN | disclosed |
| US-20220143128-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | BCELL SOLUTIONS, INC. (US) | 2022-05-12 | — | — | US | disclosed |
| EP-3142665-B1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | APAXEN (BE) | 2021-01-20 | — | — | EP | disclosed |
| US-20200377457-A1 | MIF MODULATORS | UNIV YALE (US) | 2020-12-03 | — | — | US | disclosed |
| US-20190270706-A1 | MIF MODULATORS | UNIV YALE (US) | 2019-09-05 | — | — | US | disclosed |
| US-10358453-B2 | Antiviral compounds | ALIOS BIOPHARMA, INC. (US) | 2019-07-23 | — | — | US | disclosed |
| US-10202343-B2 | MIF modulators | YALE UNIVERSITY (US) | 2019-02-12 | — | — | US | disclosed |
| US-10071080-B2 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIFCARE (FR) | 2018-09-11 | — | — | US | disclosed |
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | disclosed |
| US-20180162813-A1 | MIF MODULATORS | YALE UNIVERSITY | 2018-06-14 | — | — | US | disclosed |
| EP-2944310-B1 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIFCARE (FR) | 2018-03-21 | — | — | EP | disclosed |
| US-9834525-B2 | Inhibitors of paxillin function and related compositions and methods | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663537-B2 | Chemokine receptor antagonists and methods of use | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9643922-B2 | MIF modulators | YALE UNIVERSITY (US) | 2017-05-09 | — | — | US | disclosed |
| US-9617212-B2 | Isoindolin-1-ones as macrophage migration inhibitory factor (MIF) inhibitors | CONTROLLED CHEMICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Universite Paris-Saclay (FR) | 2017-03-23 | — | — | US | disclosed |
| EP-3142665-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | Mifcare (FR) | 2017-03-22 | — | — | EP | disclosed |
| EP-1688418-B1 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARM INC (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9540322-B2 | MIF modulators | YALE UNIVERSITY (US) | 2017-01-10 | — | — | US | disclosed |
| EP-3102567-A1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | University of Tennessee Research Foundation (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20160347725-A1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION | 2016-12-01 | — | — | US | disclosed |
| EP-3083608-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2016-10-26 | — | — | EP | disclosed |
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC | 2016-09-29 | — | — | US | disclosed |
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC | 2016-09-29 | — | — | US | disclosed |
| WO-2016138158-A1 | ANTIVIRAL COMPOUNDS | ALIOS BIOPHARMA, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | Janssen Pharmaceuticals, Inc. | 2016-08-25 | — | — | US | disclosed |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-30 | — | — | US | disclosed |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-30 | — | — | US | disclosed |
| US-9328077-B2 | Bicyclic PKM2 activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-05-03 | — | — | US | disclosed |
| US-9328077-B2 | Bicyclic PKM2 activators | AGIOS PHARMACEUTICALS, INC (US) | 2016-05-03 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2016-02-04 | — | — | US | disclosed |
| WO-2015173433-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIFCARE (FR) | 2015-11-19 | — | — | WO | disclosed |
| EP-2944310-A1 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | Mifcare (FR) | 2015-11-18 | — | — | EP | disclosed |
| US-9181231-B2 | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia | AGIOS PHARMACEUTICALS, INC (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181231-B2 | Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia | AGIOS PHARMACEUTICALS, INC (US) | 2015-11-10 | — | — | US | disclosed |
| WO-2015120059-A1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | YATES CHARLES RYAN (US) | 2015-08-13 | — | — | WO | disclosed |
| WO-2015095370-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| WO-2015095052-A1 | ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS | CONTROLLED CHEMICALS, INC. (US) | 2015-06-25 | — | — | WO | disclosed |
| US-20150175540-A1 | ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS | CONTROLLED CHEMICALS, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KIRIN CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC (US) | 2014-06-26 | — | — | US | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-8653096-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-01-09 | — | — | US | disclosed |
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS, INC (US) | 2014-01-09 | — | — | US | disclosed |
| EP-2391602-B1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2013-12-04 | — | — | EP | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-8507488-B2 | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors | IRM LLC (BM) | 2013-08-13 | — | — | US | disclosed |
| US-8362065-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-29 | — | — | US | disclosed |
| WO-2012151440-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | AGIOS PHARMACEUTICALS, INC. (US) | 2012-11-08 | — | — | WO | disclosed |
| WO-2012088314-A1 | BICYCLIC PKM2 ACTIVATORS | AGIOS PHARMACEUTICALS, INC. (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120071471-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | NEUROSEARCH A/S (DK) | 2012-03-22 | — | — | US | disclosed |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-03-08 | — | — | US | disclosed |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2012-02-23 | — | — | US | disclosed |
| EP-1901776-B1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | BOEHRINGER INGELHEIM INT (DE) | 2012-02-22 | — | — | EP | disclosed |
| US-20120040974-A1 | MIF MODULATORS | YALE UNIVERSITY (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120004261-A1 | MIF MODULATORS | YALE UNIVERSITY (US) | 2012-01-05 | — | — | US | disclosed |
| US-8084620-B2 | Carbazole carboxamide compounds useful as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-12-27 | — | — | US | disclosed |
| EP-2391602-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | Bristol-Myers Squibb Company (US) | 2011-12-07 | — | — | EP | disclosed |
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058287-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| WO-2011140202-A2 | MIF MODULATORS | YALE UNIVERSITY (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | IRM LLC (BM) | 2011-07-07 | — | — | US | disclosed |
| EP-2326631-A2 | MIF MODULATORS | Yale University (US) | 2011-06-01 | — | — | EP | disclosed |
| EP-1911749-B1 | New long-working Beta-2 agonists and their use as medicine | BOEHRINGER INGELHEIM INT (DE) | 2010-10-27 | — | — | EP | disclosed |
| US-20100267714-A1 | MIF MODULATORS | YALE UNIVERSITY | 2010-10-21 | — | — | US | disclosed |
| US-7795251-B2 | 3,4-dihydro-benzo[e][1,3]oxazin-2-ones | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795251-B2 | 3,4-dihydro-benzo[e][1,3]oxazin-2-ones | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| US-7795251-B2 | 3,4-dihydro-benzo[e][1,3]oxazin-2-ones | NOVARTIS AG (CH) | 2010-09-14 | — | — | US | disclosed |
| WO-2010080481-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-07-15 | — | — | WO | disclosed |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-06-24 | — | — | US | disclosed |
| EP-1805170-B1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2010-04-14 | — | — | EP | disclosed |
| EP-2167498-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2010-03-31 | — | — | EP | disclosed |
| WO-2010021693-A2 | MIF MODULATORS | YALE UNIVERSITY (US) | 2010-02-25 | — | — | WO | disclosed |
| US-7645776-B2 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | HOFFMANN-LA ROCHE INC. (US) | 2010-01-12 | — | — | US | disclosed |
| EP-1959951-B1 | HETEROARYL SUBSTITUTED PIPERIDINE DERIVATIVES AS L-CPT1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-7632834-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-15 | — | — | US | disclosed |
| WO-2009140128-A2 | COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | IRM LLC (BM) | 2009-11-19 | — | — | WO | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| US-7541365-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-7541365-B2 | Chemokine receptor antagonists and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-06-02 | — | — | US | disclosed |
| US-20090099175-A1 | Phosphodiesterase 10 inhibitors | MEMORY PHARMACEUTICALS CORPORATION | 2009-04-16 | — | — | US | disclosed |
| WO-2008157210-A1 | COMPOUNDS AND COMPOSITIONS AS ITPKB INHIBITORS | IRM LLC (BM) | 2008-12-24 | — | — | WO | disclosed |
| EP-1989195-A1 | PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2008-11-12 | — | — | EP | disclosed |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | BOUYSSOU THIERRY | 2008-08-14 | — | — | US | disclosed |
| US-7378416-B2 | MIF-inhibitors | NOVARTIS AG (CH) | 2008-05-27 | — | — | US | disclosed |
| US-7378416-B2 | MIF-inhibitors | NOVARTIS AG (CH) | 2008-05-27 | — | — | US | disclosed |
| US-7375104-B2 | Long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| EP-1911749-A1 | New long-working Beta-2 agonists and their use as medicine | Boehringer Ingelheim International GmbH (DE) | 2008-04-16 | — | — | EP | disclosed |
| CN-101160295-A | 3, 4-dihydro-benzo [ E ] [1,3] * oxazin-2-ones | NOVARTIS AG NOVARTIS PHARMA GM (CH) | 2008-04-09 | — | — | CN | disclosed |
| CN-101160295-A | 3, 4-dihydro-benzo [ E ] [1,3] * oxazin-2-ones | NOVARTIS AG NOVARTIS PHARMA GM (CH) | 2008-04-09 | — | — | CN | disclosed |
| EP-1901776-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE | Boehringer Ingelheim International GmbH (DE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1874742-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1874742-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | Novartis AG (CH) | 2008-01-09 | — | — | EP | disclosed |
| EP-1711480-B1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2007-12-19 | — | — | EP | disclosed |
| EP-1853625-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20070219189-A1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2007-09-20 | — | — | US | disclosed |
| US-20070219189-A1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2007-09-20 | — | — | US | disclosed |
| US-7271176-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271176-B2 | Chemokine receptor antagonists and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| WO-2007103260-A1 | PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| CN-101035782-A | MIF inhibitors | NOVARTIS AG (CH) | 2007-09-12 | — | — | CN | disclosed |
| EP-1805170-A1 | MIF-INHIBITORS | Novartis AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| EP-1805170-A1 | MIF-INHIBITORS | Novartis AG (CH) | 2007-07-11 | — | — | EP | disclosed |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-07 | — | — | US | disclosed |
| US-20070066609-A1 | Long acting beta-2-agonists and their use as medicaments | BOUYSSOU THIERRY | 2007-03-22 | — | — | US | disclosed |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-02-15 | — | — | US | disclosed |
| WO-2007003554-A1 | NOVEL MEDICINAL COMBINATIONS WHICH ARE USED FOR TREATING RESPIRATORY TRACT DISEASES AND CONTAIN BETA-2 LONG-ACTING AGONISTS AND AT LEAST ONE OTHER TYPE OF ACTIVE SUBSTANCE. | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-11 | — | — | WO | disclosed |
| US-7160882-B2 | Long acting β-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-01-09 | — | — | US | disclosed |
| WO-2006108671-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| WO-2006108671-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | NOVARTIS AG (CH) | 2006-10-19 | — | — | WO | disclosed |
| EP-1711480-A1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | Boehringer Ingelheim International GmbH (DE) | 2006-10-18 | — | — | EP | disclosed |
| WO-2006081272-A2 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR | GENENTECH, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
| WO-2006045505-A1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006045505-A1 | MIF-INHIBITORS | NOVARTIS AG (CH) | 2006-05-04 | — | — | WO | disclosed |
| EP-1119562-B1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2005-12-14 | — | — | EP | disclosed |
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-10-13 | — | — | US | disclosed |
| WO-2005070908-A1 | NOVEL LONG-WORKING BETA-2-AGONISTS AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-08-04 | — | — | WO | disclosed |
| EP-1490385-A2 | JAGGED 2 INHIBITORS FOR INDUCING APOPTOSIS | ISIS PHARMACEUTICALS, INC. (US) | 2004-12-29 | — | — | EP | disclosed |
| US-20030232440-A1 | Antisense modulation of STAT1 expression | ISIS PHARMACEUTICALS INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003102008-A1 | ANTISENSE MODULATION OF TRANSCRIPTION FACTOR DP-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003102242-A1 | NOTCH 1 INHIBITORS FOR INDUCING APOPOTOSIS | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2003077848-A2 | JAGGED 2 INHIBITORS FOR INDUCING APOPTOSIS | ISIS PHARMACEUTICALS, INC. (US) | 2003-09-25 | — | — | WO | disclosed |
| US-20030158222-A1 | 2-3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (an-tipsychotic agents) | SMITHKLINE BEECHAM P.L.C. | 2003-08-21 | — | — | US | disclosed |
| WO-2003057142-A2 | ANTISENSE MODULATION OF MACROPHAGE INFLAMMATORY PROTEIN 3-ALPHA EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-07-17 | — | — | WO | disclosed |
| US-6521638-B1 | Such as 2-(2-(1-(4-(3-(3-methanesulfonyl)phenylpropenoyl)-amino)cyclohexyl)ethyl) -2,3-dihydro-1H-isoindole; amidation of amine and carbonyl halide | SMITHKLINE BEECHAM P.L.C. (DE) | 2003-02-18 | — | — | US | disclosed |
| EP-1119562-A1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM PLC (GB) | 2001-08-01 | — | — | EP | disclosed |
| WO-2000021950-A1 | 2,3-DIHYDRO-1H-ISOINDOLE DERIVATIVES USEFUL AS MODULATORS OF DOPAMINE D3 RECEPTORS (ANTIPSYCHOTIC AGENTS) | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-04-20 | — | — | WO | disclosed |
| US-5919778-A | Cyclic amide derivatives | EISAI CO., LTD. (JP) | 1999-07-06 | — | — | US | disclosed |
| EP-0677516-B1 | Cyclic amide derivatives | EISAI CO LTD (JP) | 1998-09-02 | — | — | EP | disclosed |
| EP-0566018-B1 | Benzoxazinone and benzothiazinone derivatives endowed with cardiovascular activity | ITALFARMACO SPA (IT) | 1998-08-05 | — | — | EP | disclosed |
| US-5654308-A | PREVENT OR TREAT DISEASE DUE TO INSUFFICIENT CHOLINE FUNCTION | EISAI CO., LTD. (JP) | 1997-08-05 | — | — | US | disclosed |
| US-5620976-A | PREVENTION AND TREATMENT OF DISEASES DUE TO INSUFFICIENCY OF THE CENTRAL CHOLINE FUNCTIONS | EISAI CO., LTD. (JP) | 1997-04-15 | — | — | US | disclosed |
| EP-0742216-A2 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1996-11-13 | — | — | EP | disclosed |
| US-5521182-A | ACETYLCHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 1996-05-28 | — | — | US | disclosed |
| US-5504088-A | ACETYLCHOLINE ESTERASE INHIBITORS; ALZHEIMER'S DISEASE AND OTHER DISEASES CAUSED BY A LOW CONCENTRATION OF CHOLINE | EISAI CO., LTD. (JP) | 1996-04-02 | — | — | US | disclosed |
| US-5480882-A | Benzoxazinone and benzothiazinone derivatives having cardiovascular activity | ITALFARMACO S.P.A. (IT) | 1996-01-02 | — | — | US | disclosed |
| EP-0677516-A1 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1995-10-18 | — | — | EP | disclosed |
| EP-0490183-B1 | Benzoxazinone and benzothiazinone derivatives endowed with cardiovascular activity | ITALFARMACO SPA (IT) | 1995-04-19 | — | — | EP | disclosed |
| US-5292735-A | Cyclic amide derivatives | EISAI CO., LTD. (JP) | 1994-03-08 | — | — | US | disclosed |
| EP-0566018-A2 | Benzoxazinone and benzothiazinone derivatives endowed with cardiovascular activity | ITALFARMACO S.p.A. (IT) | 1993-10-20 | — | — | EP | disclosed |
| US-5189034-A | Vasodilating, antianginal agents | ITALFARMACO S.P.A. (IT) | 1993-02-23 | — | — | US | disclosed |
| EP-0490183-A1 | Benzoxazinone and benzothiazinone derivatives endowed with cardiovascular activity | ITALFARMACO S.p.A. (IT) | 1992-06-17 | — | — | EP | disclosed |
| EP-0468187-A2 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1992-01-29 | — | — | EP | disclosed |
| EP-0468187-A2 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (41 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066609-A1 | Long acting beta-2-agonists and their use as medicaments | ADRB2, ADRB1, CHRM1 | GAA 4176/4885NPSR1 481/4885MAOA 1254/4885 |
| US-20050227975-A1 | New long acting beta-2-agonists and their use as medicaments | ADRB2, ADRA2A, ADRB1 | GAA 3786/4885NPSR1 158/4885MAOA 1018/4885 |
| US-20140011804-A1 | BICYCLIC PKM2 ACTIVATORS | PDK2, PDK1, PDK3 | GAA 2394/4885NPSR1 4642/4885MAOA 3783/4885 |
| US-20160347725-A1 | INHIBITORS OF PAXILLIN FUNCTION AND RELATED COMPOSITIONS AND METHODS | CTTN, PTK2, CDC42 | GAA 4284/4885NPSR1 4102/4885MAOA 4595/4885 |
| US-20120058996-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | GAA 3409/4885NPSR1 3582/4885MAOA 3150/4885 |
| US-11584717-B2 | MIF modulators | MIF, HMGB2, HMGB3 | GAA 3661/4885NPSR1 354/4885MAOA 3417/4885 |
| US-20110166133-A1 | FUSED NITROGEN CONTAINING HETEROCYCLES AND COMPOSITIONS THEREOF AS KINASE INHIBITORS | ALK, ROS1, FLT3 | GAA 3266/4885NPSR1 1688/4885MAOA 1885/4885 |
| US-20070037781-A1 | Novel combinations of medicaments for the treatment of respiratory diseases containing long-acting beta-agonists and at least one additional active ingredient | ADRB2, ADRA2A, ADRB1 | GAA 628/4885NPSR1 225/4885MAOA 740/4885 |
| US-20160280697-A1 | THERAPEUTICALLY ACTIVE COMPOSITIONS AND THEIR METHODS OF USE | PDK1, PDK2, PCK1 | GAA 846/4885NPSR1 4768/4885MAOA 4537/4885 |
| US-20090156588-A1 | 3,4-DIHYDRO-BENZO[E][1,3]OXAZIN-2-ONES | CYP2C8, CYP2C18, CYP4B1 | GAA 1224/4885NPSR1 204/4885MAOA 198/4885 |
| US-20200377457-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | GAA 3661/4885NPSR1 354/4885MAOA 3417/4885 |
| US-20180162813-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | GAA 3661/4885NPSR1 354/4885MAOA 3417/4885 |
| US-20220143128-A1 | METHODS FOR TREATING TRAUMATIC BRAIN INJURY | CD74, MIF, MICA | GAA 2479/4885NPSR1 1387/4885MAOA 2266/4885 |
| US-20030158222-A1 | 2-3-dihydro-1H-isoindole derivatives useful as modulators of dopamine D3 receptors (an-tipsychotic agents) | OPRD1, DRD3, OPRM1 | GAA 4479/4885NPSR1 31/4885MAOA 218/4885 |
| US-20120040974-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | GAA 3661/4885NPSR1 354/4885MAOA 3417/4885 |
| US-20070219189-A1 | MIF-INHIBITORS | MIF, FOXM1, CCR8 | GAA 2358/4885NPSR1 375/4885MAOA 1138/4885 |
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | CYP4A11, CYP11B2, NQO1 | GAA 4360/4885NPSR1 1564/4885MAOA 2381/4885 |
| US-10071080-B2 | MIF inhibitors for the acute or chronic treatment of pulmonary hypertension | MIF, CCL11, PGF | GAA 3523/4885NPSR1 218/4885MAOA 2626/4885 |
| US-20140179694-A1 | PYRUVATE KINASE ACTIVATORS FOR USE FOR INCREASING LIFETIME OF THE RED BLOOD CELLS AND TREATING ANEMIA | PCK1, PDK2, PFKP | GAA 565/4885NPSR1 4462/4885MAOA 3942/4885 |
| US-10358453-B2 | Antiviral compounds | MAVS, SARS1, ZC3HAV1 | GAA 236/4885NPSR1 4060/4885MAOA 3411/4885 |
| US-20100160303-A1 | CARBAZOLE CARBOXAMIDE COMPOUNDS USEFUL AS KINASE INHIBITORS | BTK, FLT3, JAK1 | GAA 3409/4885NPSR1 3582/4885MAOA 3150/4885 |
| US-20160244460-A1 | ANTIVIRAL COMPOUNDS | MAVS, SARS1, ZC3HAV1 | GAA 236/4885NPSR1 4060/4885MAOA 3411/4885 |
| US-20090281081-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREFOR | ACKR3, CCL11, CCR7 | GAA 2975/4885NPSR1 159/4885MAOA 4309/4885 |
| US-20120004261-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | GAA 3661/4885NPSR1 354/4885MAOA 3417/4885 |
| US-20100267714-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | GAA 3661/4885NPSR1 354/4885MAOA 3417/4885 |
| US-20240408093-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | FGFR3, FGFR1, ERBB3 | GAA 3195/4885NPSR1 3403/4885MAOA 4849/4885 |
| US-20120046311-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | GAA 3106/4885NPSR1 79/4885MAOA 3525/4885 |
| US-20160031908-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | GAA 3106/4885NPSR1 79/4885MAOA 3525/4885 |
| US-20090099175-A1 | Phosphodiesterase 10 inhibitors | PDE7A, PDE7B, PDE10A | GAA 69/4885NPSR1 885/4885MAOA 143/4885 |
| US-20080194550-A1 | LONG ACTING BETA-2-AGONISTS AND THEIR USE AS MEDICAMENTS | ADRB2, ADRB1, CHRM1 | GAA 4186/4885NPSR1 483/4885MAOA 1251/4885 |
| US-20140371207-A1 | CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF | ACKR3, CCR2, CXCR2 | GAA 3106/4885NPSR1 79/4885MAOA 3525/4885 |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | GAA 3620/4885NPSR1 4579/4885MAOA 4378/4885 |
| US-20150175540-A1 | ISOINDOLIN-1-ONES AS MACROPHAGE MIGRATION INHIBITORY FACTOR (MIF) INHIBITORS | MIF, MACF1, MYADM | GAA 3343/4885NPSR1 2207/4885MAOA 1835/4885 |
| US-10202343-B2 | MIF modulators | MIF, HMGB2, HMGB3 | GAA 3661/4885NPSR1 354/4885MAOA 3417/4885 |
| US-20170079958-A1 | MIF INHIBITORS FOR THE ACUTE OR CHRONIC TREATMENT OF PULMONARY HYPERTENSION | MIF, CCL11, PGF | GAA 3523/4885NPSR1 218/4885MAOA 2626/4885 |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | GAA 3620/4885NPSR1 4579/4885MAOA 4378/4885 |
| US-20230416262-A1 | TRPML MODULATORS | TRPM2, TRPM4, TRPM5 | GAA 2832/4885NPSR1 508/4885MAOA 2193/4885 |
| US-20120071471-A1 | NOVEL BENZOXAZINONE DERIVATIVES USEFUL FOR THE TREATMENT OF CNS DISORDERS | PMP22, GRIN2C, NLN | GAA 1720/4885NPSR1 143/4885MAOA 396/4885 |
| US-20070060592-A1 | heterocylic amines such as 2-(5-{3-[4-(4-Chloro-2-methyl-phenyl)-piperazin-1-yl]-propylidene}-5,11-dihydro-10-oxa-1-aza-dibenzo[a,d]cyclohepten-7-yl)-propan-2-ol, used for treating diseases associated with aberrant leukocyte recruitment and/or activation | THPO, NFATC1, HPGDS | GAA 1412/4885NPSR1 1327/4885MAOA 370/4885 |
| US-20070129544-A1 | (R)-1-{2-[3-(4-Methoxy-phenyl)-[1,2,4]oxadiazol-5-yl]-piperidin-1-yl}-2-phenoxy-ethanone; carnitine-dependent palmitoyltransferases (CPTs); reduce liver beta -oxidation, consequently inhibit gluconeogenesis and therefore counteract hyperglycemia | CPT1A, CPT1B, CPT2 | GAA 1311/4885NPSR1 3092/4885MAOA 1684/4885 |
| US-20190270706-A1 | MIF MODULATORS | MIF, HMGB2, HMGB3 | GAA 3661/4885NPSR1 354/4885MAOA 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.